AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was founded in 1991 and is headquartered in Maynard, Massachusetts. AquaBounty Technologies, Inc. is a subsidiary of Intrexon Corporation.
Industry, Sector and Symbol
Industry Fishing, hunting & trapping
Sub-IndustryN/A
SectorMedical
Phone978-648-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.28 million
Profitability
Miscellaneous
Employees37
OptionableNot Optionable
Aquabounty Technologies (NASDAQ:AQB) Frequently Asked Questions
What is Aquabounty Technologies' stock symbol?
Aquabounty Technologies trades on the NASDAQ under the ticker symbol "AQB."
How were Aquabounty Technologies' earnings last quarter?
Aquabounty Technologies Inc (NASDAQ:AQB) posted its earnings results on Friday, November, 2nd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.14 million. View Aquabounty Technologies' Earnings History.
When is Aquabounty Technologies' next earnings date?
What price target have analysts set for AQB?
1 analysts have issued 12-month price targets for Aquabounty Technologies' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Aquabounty Technologies' share price to reach $4.00 in the next year. This suggests a possible upside of 77.8% from the stock's current price. View Analyst Price Targets for Aquabounty Technologies.
What is the consensus analysts' recommendation for Aquabounty Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquabounty Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquabounty Technologies.
What are Wall Street analysts saying about Aquabounty Technologies stock?
Here are some recent quotes from research analysts about Aquabounty Technologies stock:
- 1. According to Zacks Investment Research, "AquaBounty Technologies, Inc. is a biotechnology company. It focused on enhancing productivity in aquaculture. The company operates primarily in Maynard, Massachusetts and Fortune, Prince Edward Island. AquaBounty Technologies, Inc. is based in Maynard, United States. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We are initiating coverage of Buy rating and setting a conservative $3.75 price target on what we see as the leading accelerating technology in creating and growing Atlantic salmon, arguably one of if not the healthiest protein choices as a key original source for the richest long-chain omega-3 fatty acids, EPA (eicosapentaenoic) and DHA (docosahexaenoic). Atlantic salmon has experienced moderately increasing consumption worldwide that has driven the creation of 3.2M metric ton (MT) global farmed Atlantic salmon production—roughly a $30B market—that represents a fraction of the approximate $177B global aquaculture market. Over the past eight years, U.S. imports of Atlantic salmon, estimated in the 300,000MT range—or $2.8B at wholesale—have escalated at rates above global Atlantic salmon production, signaling future domestic price increases." (6/28/2018)
Has Aquabounty Technologies been receiving favorable news coverage?
Media coverage about AQB stock has trended very positive on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aquabounty Technologies earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Aquabounty Technologies' key competitors?
Some companies that are related to Aquabounty Technologies include Fonar (FONR), Fennec Pharmaceuticals (FENC), Ardelyx (ARDX), Spero Therapeutics (SPRO), Neon Therapeutics (NTGN), Concord Medical Services (CCM), Chimerix (CMRX), Adamis Pharmaceuticals (ADMP), Surface Oncology (SURF), Galmed Pharmaceuticals (GLMD), RenovaCare (RCAR), Imprimis Pharmaceuticals (IMMY), OASMIA PHARMACE/ADR (OASM), Sensus Healthcare (SRTS) and Marinus Pharmaceuticals (MRNS).
Who are Aquabounty Technologies' key executives?
Aquabounty Technologies' management team includes the folowing people:
- Dr. Ronald L. Stotish, CEO, Pres & Exec. Director (Age 69)
- Mr. David A. Frank, CFO & Treasurer (Age 58)
- Mr. Alejandro Rojas, Chief Operating Officer of Aquabounty Farms (Age 56)
- Mr. Christopher H. Martin, Gen. Counsel & Company Sec. (Age 52)
- Mr. Henry C. Clifford, VP of Sales & Marketing (Age 64)
How do I buy shares of Aquabounty Technologies?
Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquabounty Technologies' stock price today?
One share of AQB stock can currently be purchased for approximately $2.25.
How big of a company is Aquabounty Technologies?
Aquabounty Technologies has a market capitalization of $33.97 million and generates $53.28 million in revenue each year. The company earns $-9,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Aquabounty Technologies employs 37 workers across the globe.
What is Aquabounty Technologies' official website?
How can I contact Aquabounty Technologies?
Aquabounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected]
MarketBeat Community Rating for Aquabounty Technologies (NASDAQ AQB)
MarketBeat's community ratings are surveys of what our community members think about Aquabounty Technologies and other stocks. Vote "Outperform" if you believe AQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQB will underperform the S&P 500 over the long term. You may vote once every thirty days.
